Product Information
JENTADUETO XR 2.5 MG-1,000 MG is a brand product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $8.4695 per EA under NDC 00597027094. Its NADAC has been published 476 times since Aug 23, 2017.
FDA first approved this application on May 27, 2016.
Strength
2.5; 1000 mg/1; mg/1
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597027094
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LINAGLIPTIN; METFORMIN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA208026FDA Approved
5/27/2016
On Market Since
5/27/2016
Pharmacological Classes
Price Statistics
The NADAC for JENTADUETO XR 2.5 MG-1,000 MG has been published 476 times since Aug 23, 2017, and over the history we have for it it has risen 38.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.4695 per EA |
|---|---|
| All-time high | $8.4718 (Sep 16, 2026) |
| All-time low | $6.1336 (Aug 23, 2017) |
| 52-week high | $8.4718 |
| 52-week low | $8.4439 |
| Median price | $8.0796 |
| Average price | $7.7492 |
| Largest weekly change | +8.0% (Jan 10, 2018) |
| Weeks tracked | 476 |
| Tracking since | Aug 23, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
linagliptin and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of JENTADUETO XR 2.5 MG-1,000 MG?
The current National Average Drug Acquisition Cost (NADAC) for JENTADUETO XR 2.5 MG-1,000 MG, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $8.4695 per EA (NDC 00597027094), effective Sep 30, 2026.
How has the price of JENTADUETO XR 2.5 MG-1,000 MG changed over time?
Over the history we have for it, the NADAC for JENTADUETO XR 2.5 MG-1,000 MG has risen 38.1%. It has been tracked across 476 weekly CMS publications since Aug 23, 2017.
What are the highest and lowest recorded NADAC prices for JENTADUETO XR 2.5 MG-1,000 MG?
Since Aug 23, 2017, the NADAC for JENTADUETO XR 2.5 MG-1,000 MG has ranged from a low of $6.1336 (Aug 23, 2017) to a high of $8.4718 (Sep 16, 2026), with a median of $8.0796 per EA.
Are there cheaper alternatives to JENTADUETO XR 2.5 MG-1,000 MG?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, JENTADUETO 2.5 MG-1,000 MG TAB, is $8.4388 per EA — about 0% below JENTADUETO XR 2.5 MG-1,000 MG.
Who manufactures JENTADUETO XR 2.5 MG-1,000 MG?
JENTADUETO XR 2.5 MG-1,000 MG (NDC 00597027094) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand product.